GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Large-Scale Genetic Analyses of Human Cancer

$310,729
Victor E Velculescu · Johns Hopkins University · R01 · FY2018 · CA

Immunopathology Core

$310,662
Cecilia C Yeung · University Of Washington · P01 · FY2025 · CA

P38, G2 Arrest, and Temozolomide Resistance in Gliomas

$310,575
University Of California San Francisco · R01 · FY2004 · CA

The Role of Egfl6 in Tumor Immunity

$310,336
Sandra Cascio · Magee-Women'S Res Inst And Foundation · R01 · FY2025 · CA

The Mammalian Cell Cycle Control and Tumor Genesis

$310,250
University Of North Carolina Chapel Hill · R01 · FY2005 · CA

Structure and Function of the Essential Cell Cycle Regulator Cdc34

$310,000
Shaun Olsen · University Of Texas Hlth Science Center · R01 · FY2022 · GM

Therapeutic targeting of stratifin structure and function

$309,964
Jian-Ting Zhang · Indiana University Indianapolis · R01 · FY2011 · CA

Therapeutic targeting of stratifin structure and function

$309,964
Jian-Ting Zhang · Indiana University Indianapolis · R01 · FY2012 · CA

(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy

$309,948
Elad Ziv · University Of California, San Francisco · R01 · FY2023 · CA

Role of RecQ Helicases to Prevent Senescence By c-Myc

$309,930
Denise A. Galloway · Fred Hutchinson Cancer Research Center · R01 · FY2007 · AG

53BP1-Mediated Regulation of DNA Repair and Chemoresistance

$309,504
Shridar Ganesan · Rbhs -Cancer Institute Of New Jersey · R01 · FY2013 · CA

Project 2: Targeting Immune Vulnerabilities in Lung Cancer

$309,392
John V. Heymach · Ut Southwestern Medical Center · P50 · FY2024 · CA

Structure and Function of the Essential Cell Cycle Regulator Cdc34

$309,000
Shaun Olsen · University Of Texas Hlth Science Center · R01 · FY2021 · GM

Project 1: Targeting Neutrophils to Enhance ICI Efficacy in NSCLC

$308,964
A. McGarry Houghton · Fred Hutchinson Cancer Center · P50 · FY2025 · CA

Mechanisms of Telomere Function

$308,820
New York University School Of Medicine · R01 · FY2005 · CA

A novel monoclonal antibody-based anti-NK cell anti-inflammatory strategy for treating autoimmune and checkpoint inhibitor induced myocarditis

$308,650
Dror Luger · Inflamma Therapeutics, Llc · R43 · FY2021 · HL

Targeting Cell Cycle Machinery For Cancer Therapy

$308,525
Temple University · R01 · FY2005 · CA

Targeting Cell Cycle Machinery For Cancer Therapy

$308,525
Temple University · R01 · FY2004 · CA

Mechanism(s) of Hepatocyte Transformation by the Hepatitis B Virus X Protein

$308,439
Ourania M. Andrisani · Purdue University · R01 · FY2013 · DK

Mrad9 Radioresistance Gene

$308,410
Columbia University Health Sciences · R01 · FY2004 · CA

Mrad9 Radioresistance Gene

$308,410
Columbia University Health Sciences · R01 · FY2003 · CA

Adaptation and Preliminary Evaluation of Energize-MBC: Cognitive Behavioral Therapy for Fatigue among Women with Metastatic Breast Cancer

$308,399
Heather S.l. Jim · H. Lee Moffitt Cancer Ctr & Res Inst · R34 · FY2025 · CA

Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBM

$308,393
E. Antonio Chiocca · Massachusetts General Hospital · P01 · FY2017 · CA

PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy

$308,387
Eric S Ubil · University Of Alabama At Birmingham · R01 · FY2022 · CA

XLF in double-strand break repair and chemo/radiosensitization

$308,039
Lawrence F Povirk · Virginia Commonwealth University · R01 · FY2015 · CA